Press Releases and News

Aphios to Present in the Chicago Cubs Room at the 2013 BIO International Convention
April 18, 2013
Woburn, Mass. – Aphios Corporation, a clinical-stage biotechnology company developing enabling technology platforms and enhanced therapeutic products for chronic, debilitating diseases and improved quality of life today announced that Dr. Trevor P. Castor, President and CEO, will present the Company's technologies, products and plans at the 2013 BIO International Convention. Dr. Castor's presentation will take place on Wednesday, April 24, 2013 at 10:00 a.m. CT in the Chicago Cubs room at the McCormick Place in Chicago, Illinois.

Aphios' lead therapeutic products include: Zindol, which has successfully completed Phase II/III clinical trials for chemotherapy induced nausea and vomiting (CINV); APH-0703, a potent protein kinase C (PKC) activator for ameliorating Alzheimer's disease and cognitive impairment with neuroprotection; APH-0812, a combination therapy consisting of PKC modulators with or without HDAC inhibitors currently entering a Phase I/IIa clinical trial for HIV latency in Spain; AMPI-109, a nontoxic Vitamin D derivative for hormone refractory prostate cancer (HRPCA); and APH-0907, a nanotechnology formulation of insulin in biodegradable polymers that makes insulin orally bioavailable through protection in the digestive tract and stomach, and delivery in the small intestine.

According to Dr. Castor, "We are raising capital to continue clinical development of Zindol and file an NDA for its use as an adjuvant to conventional antiemetics to treat CINV. Zindol also has additional potential applications in post-operative nausea and vomiting, pregnancy related nausea and vomiting and motion sickness nausea and vomiting. The US marketplace for Zindol® could be as high as $3.3 billion."

Dr. Castor will present Aphios' business strategy and financial plans to complete the development and commercialization of Zindol and other clinical programs, including APH-0703 for Alzheimer's disease and cognitive impairment, APH-0812 for HIV latency, AMPI-109 for prostate cancer and APH-0907 for diabetes. Plans will also be presented for the continued manufacturing, distribution and sales of quality-of-life medicines for health maintenance and disease prevention.

ABOUT THE BIO INTERNATIONAL CONVENTION

The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. The Convention also features the BIO Business Forum, a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities. For registration, conference agenda and exhibitor information, visit convention.bio.org

ABOUT APHIOS CORPORATION

Aphios Corporation, a clinical-stage biotechnology company, is developing green, enabling technology platforms for improving drug discovery and manufacturing, nanotechnology drug delivery, viral vaccines, and virus-free human plasma and biologics. Based on these platforms, Aphios is developing quality-of-life medicines for health maintenance and disease prevention, and enhanced therapeutics for the treatment of certain cancers and supportive care, HIV, diabetes and Alzheimer's disease.

This Press Release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and is subject to the safe harbors created thereby. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

###